Creating shareholder value through M&A in the life sciences sector
In the January 2016 edition of Financier Worldwide, Dr. Gregory K. Bell discusses how mergers and acquisitions can create shareholder value in the life...
The CRA Life Sciences team has a broad range of experience in complex shareholder lawsuits and appraisal disputes involving life sciences and healthcare companies. CRA assists clients across all phases of the securities litigation process, including responding to pre-litigation SEC investigations, class certification, discovery, materiality, loss causation, damages, and settlement negotiations. CRA supports clients in disputes arising from mergers and acquisitions by providing industry expertise in evaluating claims regarding drug development and commercialization and other issues. Our experts provide valuation opinions related appraisal lawsuits brought by dissenter or minority shareholders, and estimated damages related to shareholder disputes for breach of contingent valuation rights agreements.
Engagements
- 01CRA assesses pharmaceutical investor claims in Delaware Chancery CourtIn a matter before the Delaware Chancery Court, CRA was retained on behalf of a pharmaceutical company facing an investor suit alleging breach of fiduciary...View engagement
- 02CRA evaluates commercial efforts to develop a MS drug with respect contractual obligations following mergerCRA assessed commercial efforts to develop and commercialize a MS drug with respect to obligations stemming from the acquisition of Genzyme Corporation by...View engagement